Elm Partners Management LLC Makes New Investment in Eli Lilly and Company $LLY

Elm Partners Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,611 shares of the company’s stock, valued at approximately $2,815,000.

A number of other hedge funds also recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. Nuveen LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. HSBC upped their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Eli Lilly and Company Trading Up 2.2%

LLY stock opened at $862.96 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company’s 50-day simple moving average is $780.74 and its 200 day simple moving average is $771.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a market capitalization of $816.76 billion, a PE ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Insider Activity

In other news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.